Valomaciclovir (MIV-606)

Therapy Area
An NRTI addressing herpes zoster (shingles) and post-herpetic neuralgia (PHN) Also active against other herpes viruses.

Competitive Edge
Phase II results indicate reduction of shingles-related PHN more effectively than current therapy.

Licensee
Epiphany Biosciences, clinical trials against herpes zoster (phase IIb) and mononucleosis (phase IIa) are ongoing.

Last Modified: 12/05/2009